Monday, December 30, 2013

Seeking Alpha: Clovis Oncology Has An Exciting Pipeline And A Reasonable Valuation

There aren't many cheap biotechs left out there, at least not among the higher-quality ideas. To be sure, arguing that Clovis Oncology (CLVS) is undervalued after a better than 250% rise over the past year is going to strike some as ridiculous. Even so, I believe the company has multiple exciting pipeline opportunities that make this still a name worth investigating further. Although I'm a little concerned that the Street's expectations for clinical success are ahead of industry norms, early-stage data have been quite encouraging.

Please click here to read more:
Clovis Oncology Has An Exciting Pipeline And A Reasonable Valuation

No comments: